HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
USFDA concludes inspection at Vadodara facility of Bharat Parenterals’ arm
Apr-21-2026

United States Food and Drug Administration (USFDA) has concluded inspection at Bharat Parenterals’ subsidiary – Innoxel Lifesciences’ finished dosage manufacturing facility in Vadodara, Gujarat. The inspection of the General Injectables Block was conducted from April 13, 2026 to April 17, 2026 and April 20, 2026.

At the conclusion of the inspection, the USFDA has issued five observations under a Voluntary Action Indicated (VAI) classification. The final Establishment Inspection Report (EIR) is awaited.

The General Injectables Block is a key manufacturing facility supporting the supply of sterile injectable formulations to regulated markets, including the United States and the European Union.

Bharat Parenterals is engaged in to the business of the Pharmaceuticals & Drugs.

  RELATED NEWS >>